High Court judge questions whether coronavirus should spark patent reform
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

High Court judge questions whether coronavirus should spark patent reform


Mr Justice Colin Birss says possible measures could include specialist extensions to patent terms and a more collaborative approach among the medical community

England and Wales High Court judge Mr Justice Colin Birss has mulled whether changes to the UK’s patent system could help the country be better equipped to respond to emergencies such as the coronavirus outbreak.

The head of the patents division at the High Court questioned whether patent term extensions for drugs that are only used in an emergency, and a more collaborative approach among medical professionals, could help tackle the problem.

As it stands there is no vaccine for coronavirus (COVID-19). Around 95,000 people have been infected with the virus globally and more than 3,000 of those have died. The majority of cases have come from China’s Wuhan province, but cases are also spreading around the world, including in the UK.

“Why are there no vaccines?” Birss asked, pointing out that the SARS virus of 17 years ago was also a type of coronavirus and that unpredictability should not be a factor in a lack of vaccine development.

He added: “The patent system was fundamentally set up to incentivise innovation and to make money for inventors over a long period of time. A pill to treat this type of illness would not make as much cash, as you would only need to take it once.”

Birss said it would be a challenge to fund research into products where there is a public need but where the return is low over a long period of time.

Perhaps, he suggested, there should be a longer patent term for medicines of this type that can be bought over the counter in an emergency.

“I’m not saying this should happen and I don’t have an action plan with me but I’m asking whether this could be an option,” he said.

Also worth pointing out, said Birss, is that the patent system was not set up to encourage collaboration, but that, over time, this attitude has changed.

“It’s clear this is not true any more,” Birss said, referencing litigation surrounding fair, reasonable and non-discriminatory licensing in the telecoms industry.

He pointed out that in the tech community, group conversations on collaboration and licensing, and how to work out industry standards, do take place.

“Maybe standard-setting should be extended to also allow medical companies to share their ideas in this way? We may see further moves towards sets of patent systems with their own rules,” Birss said.

Birss, speaking at Managing IP’s International Patent Forum in London today, also addressed the shortage of specialist patent judges at the High Court.

As it stands, Birss is the only full-time judge able to hear category 4 and 5 patent cases (the most complex kind).

“I am the sole shopkeeper at the moment but we are managing,” Birss stressed. He pointed out that deputy judges and other IP specialists, including recently appointed Court of Appeal judge Lord Justice Richard Arnold and Intellectual Property Enterprise Court judge Richard Hacon, have both helped share the load.

Birss said he is hopeful that the court – which last year had three full-time patent judges – will be back to full capacity by October this year.

more from across site and ros bottom lb

More from across our site

The firm was among multiple winners at a record-breaking 2024 ceremony held in London on April 11
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
The Americas research cycle has commenced. Do not miss this opportunity to nominate your work!
Increased and new patent fees could affect prosecution strategies for law firms and companies, according to sources
Five former Oblon lawyers felt that joining Merchant & Gould would help them offer the right prices to entice clients
The UK may not be a UPC member but its firms are still acting in proceedings, with Carpmaels among the most prominent
Naomi Pearce of Pearce IP shares how she is helping her firm become a life sciences leader and how generous policies have helped attract top talent
The Court of Appeal has dismissed an appeal filed by Ocado, in what was a key test for transparency at the new court
Each week Managing IP speaks to a different IP lawyer or professional about their life and career
INTA is calling out ‘immoral’ unregistered attendees at the association’s annual meeting, but the debate is more nuanced
Gift this article